Phelan-McDermid syndrome (PMS), a rare and complex genetic disorder that profoundly impacts neurological and physical development, may be significantly more prevalent than historical medical estimates have suggested. According to a landmark study recently published in the scientific journal Autism Research, researchers at the Seaver Autism Center for Research and Treatment at Mount Sinai have calculated that the condition affects approximately 1 in every 7,300 people. This revised estimate translates to roughly 13.7 cases per 100,000 individuals, indicating that upwards of 45,000 people may be living with the condition in the United States alone.
The findings represent a dramatic shift in the medical community’s understanding of PMS. For years, the disorder was classified as an ultra-rare condition, with precise prevalence figures remaining largely elusive due to diagnostic limitations and a historic lack of widespread genetic screening. By examining a vast repository of genetic and clinical data, researchers have been able to bridge the gap between known clinical diagnoses and the true statistical presence of the disorder in the broader population. This expanded epidemiological perspective arrives at a critical juncture in medical science, coinciding with the rapid advancement of targeted clinical trials and precision medicine therapies designed to address the root biological causes of the syndrome.
Understanding Phelan-McDermid Syndrome and the SHANK3 Connection
Phelan-McDermid syndrome is fundamentally a genetic disorder triggered by a deletion or mutation involving the SHANK3 gene, located on the long arm of chromosome 22 (specifically region 22q13.33). The SHANK3 gene plays a crucial role in the human brain, encoding a master scaffolding protein that is essential for the formation, development, and overall function of synapses—the junctions through which neurons communicate with one another. When this gene is deleted, disrupted, or mutated, synaptic integrity is compromised, leading to widespread disruptions in neural circuitry.
The clinical presentation of PMS is notoriously broad, reflecting the foundational role of synaptic health in human development. Individuals diagnosed with the syndrome often face a constellation of medical, intellectual, and behavioral challenges. These can include severe speech delays or complete non-verbal communication, global developmental delays, hypotonia (low muscle tone), motor dysfunctions, epilepsy or seizure disorders, sleep disturbances, and gastrointestinal issues. Furthermore, a substantial majority of individuals diagnosed with PMS also meet the formal diagnostic criteria for autism spectrum disorder (ASD). In fact, current genetic and psychiatric research indicates that mutations and deletions affecting the SHANK3 gene account for approximately one percent of all autism spectrum disorder cases globally, making it one of the most common single-gene causes of autism.
Methodology and Data Collection: Uncovering the Hidden Population
To arrive at the revised prevalence estimate of 1 in 7,300, the research team at Mount Sinai spearheaded a massive, multi-institutional data-aggregation effort. Recognizing that traditional epidemiological methods would fall short for a rare genetic condition that is frequently misdiagnosed or entirely missed, the investigators turned to large-scale genetic testing databases and specialized autism research cohorts.
The research team analyzed genetic testing and clinical data drawn from nearly 180,000 individuals with autism spectrum disorder who had undergone formal genetic evaluations. The study synthesized information from ten distinct, high-throughput sources. These included prominent commercial and clinical genetic testing laboratories such as GeneDx, Labcorp, and Ambry Genetics, alongside large-scale academic research initiatives like the SPARK (Simons Foundation Powering Autism Research for Knowledge) study and the Autism Sequencing Consortium. Data from several major children’s hospitals were also integrated into the final analytical model.
To calculate an accurate prevalence rate, the researchers had to account for several confounding variables. They adjusted their models to compensate for undiagnosed cases within the general population, technical limitations inherent in certain types of historical genetic tests, and the subset of individuals with Phelan-McDermid syndrome who display developmental and physical symptoms but do not strictly meet the diagnostic criteria for autism spectrum disorder. By synthesizing these multifaceted datasets, the researchers produced what is widely regarded as one of the most rigorous and comprehensive prevalence estimates for PMS to date.
The Diagnostic Bottleneck: Why So Many Cases Go Unnoticed
The stark disparity between the historical understanding of PMS and the new prevalence figures highlights a systemic diagnostic bottleneck within modern healthcare infrastructure. According to the study’s lead authors, thousands of individuals remain undiagnosed simply because they are never given the opportunity to undergo comprehensive genetic testing.
Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, a certified genetic counselor at the Seaver Autism Center, and the first author of the research paper, elaborated on these systemic hurdles. "The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," Levy explained. "Families may also face insurance barriers or may receive tests that do not adequately evaluate the SHANK3 gene."
In many clinical settings, routine diagnostic evaluations for developmental delays or behavioral challenges stop at behavioral observation and standardized psychological testing. While these assessments are vital for managing symptoms, they fail to identify the underlying molecular etiology. Furthermore, standard chromosomal microarrays or older genetic sequencing panels sometimes fail to achieve the resolution required to detect small deletions or subtle mutations specifically localized to the SHANK3 gene, necessitating specialized testing approaches such as chromosomal microarray analysis with high-density probe coverage or targeted next-generation sequencing.
The Clinical Imperative of Early and Comprehensive Genetic Testing
In light of these findings, leading researchers and clinicians are strongly advocating for a paradigm shift in how pediatric neurology, psychiatry, and general pediatrics approach developmental conditions. They argue that genetic screening should no longer be viewed as a secondary or confirmatory step, but rather as an essential baseline component of clinical care for children presenting with neurodevelopmental differences.
Dr. Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, co-founder of the Autism Sequencing Consortium, and senior author of the study, emphasized the profound value of obtaining a definitive genetic diagnosis. "We recommend that every child with autism undergo genetic testing, because knowledge is power," Dr. Buxbaum stated. "These genetic findings allow researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries."
This sentiment is echoed by international biopharmaceutical and advocacy partners who supported the research initiative, including CureSHANK and Neuren Pharmaceuticals. For these organizations, identifying individuals with the syndrome is no longer merely an academic exercise; it has become an urgent clinical and ethical imperative.
Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, highlighted the driving motivations behind the collaboration. "Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative," Dr. Groth noted. "Patients cannot benefit from these advances if they never receive a diagnosis."
A New Era of Precision Medicine and Clinical Trials
The publication of this prevalence study coincides with a transformative period in Phelan-McDermid syndrome research. For decades, therapeutic interventions for PMS were strictly palliative and focused on symptom management—such as speech therapy, physical therapy, behavioral interventions, and pharmacological management of seizures or severe behavioral challenges. However, advances in molecular biology and our understanding of the SHANK3 protein have opened the door to disease-modifying therapies and precision medicine approaches.
Several clinical trials are currently underway, investigating targeted therapeutic candidates designed to restore or compensate for synaptic dysfunction caused by SHANK3 deficiencies. These therapies aim to target the underlying neurobiological mechanisms of the disorder rather than merely dampening external symptoms. For families navigating the complexities of a PMS diagnosis, the stakes are exceptionally high.
A formal genetic diagnosis now provides a gateway to a multifaceted support ecosystem. Beyond satisfying the quest for an underlying cause, a confirmed diagnosis connects families to specialized medical subspecialists who understand the unique multi-systemic comorbidities of PMS. It grants access to active research cohorts, longitudinal natural history studies, and cutting-edge clinical trials that could alter the long-term trajectory of the condition. Furthermore, patient advocacy networks and parent support groups offer vital community resources that mitigate the profound isolation often experienced by families raising children with rare genetic disorders.
Geraldine Bliss, Board Chair of CureSHANK, reflected on the validation the study provides to the patient advocacy community. "This study confirms what many families, clinicians, and advocates have suspected for years," Bliss said. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important."
Broader Implications and Global Awareness Campaigns
The findings from Mount Sinai serve as a powerful catalyst for broader healthcare initiatives, most notably CureSHANK’s ongoing push to expand global access to genetic testing. The organization continues to champion initiatives such as Start Genetic, an international awareness campaign designed to educate patients, families, primary care physicians, pediatricians, and advocacy organizations about the vital importance of prioritizing genetic testing early in the diagnostic odyssey.
The core message resonating from the medical and advocacy communities is clear: the remarkable scientific advances currently unfolding in the realm of precision medicine can only serve patients who have been accurately identified and diagnosed. As laboratories refine their screening technologies and clinical trials edge closer to regulatory milestones, identifying the tens of thousands of individuals currently missing from epidemiological registries remains the paramount challenge.
By establishing that Phelan-McDermid syndrome affects roughly 1 in 7,300 people, this study redefines the landscape of rare genetic disorders and neurodevelopmental research. It bridges the gap between statistical obscurity and clinical visibility, offering renewed hope to families worldwide while establishing a firm empirical foundation for the next generation of targeted neurological therapies.
